Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;36(5):357-366.
doi: 10.1089/AID.2019.0228. Epub 2020 Jan 22.

Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out

Affiliations

Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out

Janet P Hapgood. AIDS Res Hum Retroviruses. 2020 May.

Abstract

Intramuscular depo-medroxyprogesterone acetate (DMPA-IM) is the most widely used hormonal contraceptive in sub-Saharan Africa. Previous meta-analyses of observational studies found a significant 40%-50% increased risk associated with DMPA-IM use, relative to no contraception or infrequent condom use. This raised substantial concerns, although these studies had important limitations. Consequently, the open-label randomized Evidence for Contraceptive Options and HIV Outcomes trial was conducted, designed primarily to detect a 50% or greater difference in HIV risk between DMPA-IM, the levonorgestrel (LNG) implant, and the copper-intrauterine device. The ECHO study, published in July 2019, concluded that there is no substantial difference in HIV risk among the methods evaluated, and that all three methods are safe and highly effective. In response, the WHO relaxed the Medical Eligibility Criteria for DMPA-IM use among women at high HIV risk in August 2019. However, two of the three comparisons in the ECHO trial could rule out neither a 50% increase nor no change in HIV risk for one contraceptive compared with another. The study had limitations and the results contained considerable uncertainty. They also did not inform on associated HIV risk for any one of the individual methods due to the absence of a control group such as no contraception or only infrequent condom use. The HIV risks associated with LNG implant and copper-IUD relative to no contraception or infrequent condom use are unknown and these cannot be seen as controls, nor did the authors claim them to be. The results will be discussed in the context of their limitations, what they add to the body of work to date on contraception and HIV acquisition, and the implications of the findings and reports thereof for future research and contraceptive choice.

Keywords: DMPA; Depo-Provera; ECHO trial; HIV; contraception.

PubMed Disclaimer

Conflict of interest statement

No competing financial interests exist.

References

    1. United Nations Department of Economic and Social Affairs Population Division: Trends in contraceptive use worldwide 2015 (ST/ESA/SER.A/349). New York: United Nations, 2015
    1. Pfizer: Package leaflet: Information for the user Depo-Provera® 150 mg/ml suspension for injection. United Kingdom: Pfizer Limited, 2016
    1. United Nations, Department of Economic and Social Affairs, Population Division: Estimates and projections of family planning indicators 2019. United Nations, New York, Available at www.un.org/en/development/desa/population/theme/family-planning/cp_model... (2019), accessed September1, 2019
    1. Polis CB, Curtis KM, Hannaford PC, et al. : An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS 2016;30:2665–2683 - PMC - PubMed
    1. Morrison CS, Chen PL, Kwok C, et al. : Hormonal contraception and the risk of HIV acquisition: An individual participant data meta-analysis. PLoS Med 2015;12:e1001778. - PMC - PubMed

Publication types

MeSH terms

Substances